Dianthus Therapeutics, INC /DE/ Form 4 insider transactions

Anne Mcgeorge, a Director of Dianthus Therapeutics, Inc. /DE/, sold 7,750 shares of common stock on August 10, 2026.

Simon Read, a Director of Dianthus Therapeutics, Inc. /DE/, sold 2,777 shares of common stock on August 10, 2026.

Adam M Veness, SVP, General Counsel and Sec. of Dianthus Therapeutics, Inc. /DE/, sold 20,000 shares of common stock on August 7, 2026.

Marino Garcia, CEO AND PRESIDENT and a Director of Dianthus Therapeutics, Inc. /DE/, sold 166,000 shares of common stock on August 7, 2026.

Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, Inc. /DE/, sold 31,249 shares of common stock on July 9, 2026.

Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, Inc., reported transactions involving the purchase and sale of company common stock on June 17, 2026, executed under a Rule 10b5-1 trading plan.

EVP and Head of R&D Simrat Randhawa exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Director Steven J. Romano was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of an equity incentive.

Director Simon Read was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of an equity compensation award.

Director Alison Frances Lawton was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of an equity incentive.

Director Anne McGeorge was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of a standard equity compensation award.

Dianthus Therapeutics Director Paula Soteropoulos reported a transaction involving the sale of 599 shares of common stock on May 8, 2026, executed under a Rule 10b5-1 trading plan.

Dianthus Therapeutics EVP, CFO & CBO, Ryan Savitz, reported a transaction involving the sale of 8,224 shares of common stock.

Dianthus Therapeutics' EVP, CFO & CBO, Ryan Savitz, executed a pre-planned sale of 114,367 common shares after exercising stock options.

Dianthus Therapeutics Director Paula Soteropoulos exercised stock options and sold the resulting common shares under a pre-arranged trading plan.

Dianthus Therapeutics Director Paula Soteropoulos exercised options and sold 27,594 shares for approximately $2.15 million under a pre-arranged trading plan.

Dianthus Therapeutics CEO Marino Garcia exercised stock options to acquire 65,292 shares of common stock under a pre-arranged trading plan.

Dianthus Therapeutics CEO Marino Garcia executed a Rule 10b5-1 plan, exercising stock options and subsequently selling a significant portion of the acquired shares.

Dianthus Therapeutics' Chief Accounting Officer, Edward Carr, exercised stock options and subsequently sold all acquired shares for a significant profit under a pre-arranged trading plan.

Dianthus Therapeutics' EVP, Head of R&D, Simrat Randhawa, exercised stock options and subsequently sold 33,830 shares for over $2.75 million.

Dianthus Therapeutics' Chief Accounting Officer, Edward Carr, was granted 55,000 stock options with an exercise price of $52.46, vesting over four years.

Dianthus Therapeutics, Inc. granted its SVP, General Counsel and Secretary, Adam M. Veness, 100,000 stock options with an exercise price of $52.46, vesting over four years.

Dianthus Therapeutics, Inc. granted its EVP, Head of R&D, Simrat Randhawa, 150,000 stock options with an exercise price of $52.46, vesting over four years.

Dianthus Therapeutics' EVP, CFO & CBO, Ryan Savitz, was granted 150,000 stock options with an exercise price of $52.46, vesting over four years.

Dianthus Therapeutics CEO Marino Garcia received a grant of 355,000 stock options with an exercise price of $52.46, vesting over four years.

Dianthus Therapeutics' CFO and CBO, Ryan Savitz, exercised stock options and sold 20,000 shares of common stock for a significant profit, pursuant to a pre-arranged trading plan.

Dianthus Therapeutics EVP and Head of R&D, Simrat Randhawa, executed pre-planned sales of common stock following option exercises.

Dianthus Therapeutics CEO Marino Garcia was granted 120,000 stock options with an exercise price of $39.35, vesting over four years.

Dianthus Therapeutics' CFO & CBO, Ryan Savitz, was granted 60,000 stock options with an exercise price of $37.87, vesting over four years.

Dianthus Therapeutics' Chief Medical Officer, Simrat Randhawa, received a grant of 60,000 stock options with an exercise price of $37.87.